[Rich66]

Print version via medscape:
http://www.medscape.com/viewarticle/727807

Dr. Rebbeck and colleagues investigated a cohort of nearly 2500 women with BRCA1 or BRCA2 mutations, 10% of whom chose to undergo a risk-reducing mastectomy and 38% of whom chose a risk-reducing salpingo-oophorectomy.
No breast cancers were diagnosed in the women who underwent mastectomy during the 3 years of prospective follow-up. However, 7% of those who did not undergo a prophylactic mastectomy during a similar follow-up period were diagnosed with breast cancer.

Overall, results showed that, compared with women who did not undergo prophylactic salpingo-oophorectomy, those who underwent the procedure had an overall lower risk for ovarian cancer, including those with previous breast cancer (6% vs 1%; HR, 0.14; 95% CI, 0.04 - 0.59) and those without previous breast cancer (6% vs 2%; HR, 0.28; 95% CI, 0.12 - 0.6); a lower risk for first diagnosis of breast cancer in BRCA1 carriers (20% vs 14%; HR, 0.63; 95% CI, 0.41 - 0.96) and BRCA2 carriers (23% vs 7%; HR, 0.36; 95% CI, 0.16 - 0.82); lower all-cause mortality (10% vs 3%; HR, 0.40; 95% CI, 0.26 - 0.61); lower breast-cancer-specific mortality (6% vs 2%; HR, 0.44; 95% CI, 0.26 - 0.76); and lower ovarian-cancer-specific mortality (3% vs 0.4%; HR, 0.21; 95% CI, 0.06 - 0.80).